Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 41.e23-41.e30

  Cohn, Joshua A ^a   Wang, Chihsiung E ^b   Lakeman, Justin C ^b   Silverstein, Jonathan C ^b   Brendler, Charles B ^b   Novakovic, Kristian R ^b   McGuire, Michael S ^b   Helfand, Brian T ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Primary care; Prostate specific antigen; Screening; United States Preventive Services Task Force

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; AMBULATORY CARE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; GENERAL PRACTITIONER; HEALTH INSURANCE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SCREENING TEST; TREND STUDY;

PRIMARY CARE; PROSTATE-SPECIFIC ANTIGEN; SCREENING; UNITED STATES PREVENTIVE SERVICES TASK FORCE;

ADULT; ADVISORY COMMITTEES; AGED; GUIDELINE ADHERENCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 84890805788     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.04.013     Document Type: Article

References (30)

1. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324(17):1156-1161.
2. Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J Am Med Assoc 1993, 270(8):948-954.
3. Etzioni R., Gulati R., Falcon S., Penson D.F. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008, 28(3):323-331.
4. Jacobsen S.J., Katusic S.K., Bergstralh E.J., Oesterling J.E., Ohrt D., Klee G.G., et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J Am Med Assoc 1995, 274(18):1445-1449.
5. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
6. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009, 101(19):1325-1329.
7. Etzioni R., Penson D.F., Legler J.M., Di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94(13):981-990.
8. Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(12):1250-1261.
9. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149(3):185-191. Screening for prostate cancer: U.S.
10. Ilic D., O'Connor D., Green S., Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 2006, (3):CD004720.
11. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319.
12. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
13. Hugosson J., Carlsson S., Aus G., Bergdahl S., Khatami A., Lodding P., et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11(8):725-732.
14. Moyer V.A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(2):120-134.
15. National Ambulatory Medical Care Survey. 2009 Summary Tables [Internet]. Hyattsville, MD: National Center for Health Statistics; 2010. Available from: http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2009_namcs_web_tables.pdf.
16. Tasian G.E., Cooperberg M.R., Potter M.B., Cowan J.E., Greene K.L., Carroll P.R., et al. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis 2012, 15(2):189-194.
17. Volk R.J., Linder S.K., Kallen M.A., Galliher J.M., Spano M.S., Mullen P.D., et al. Primary care physicians' use of an informed decision-making process for prostate cancer screening. Ann Fam Med 2013, 11(1):67-74.
18. Zeliadt S.B., Hoffman R.M., Etzioni R., Gore J.L., Kessler L.G., Lin D.W. Influence of publication of US and European Prostate Cancer Screening Trials on PSA testing practices. J Natl Cancer Inst 2011, 103(6):520-523.
19. Ross JS W.R. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male medicare beneficiaries. Arch Intern Med 2012, 172(20):1601-1603.
20. Prasad S.M., Drazer M.W., Huo D., Hu J.C., Eggener S.E. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. J Am Med Assoc 2012, 307(16):1692-1694.
21. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) for Prostate Cancer Early Detection V.1.2010. (c) National Comprehensive Cancer Network, Inc 2012. All rights reserved. Accessed [January 15, 2013]. To view the most recent and complete version of the guideline, go online to. National Comprehensive Cancer Network(R), NCCN(R), NCCN Guidelines(r), and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. http://www.nccn.org.
22. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J Am Med Assoc 1995, 273(4):289-294.
23. Carter H.B., Epstein J.I., Chan D.W., Fozard J.L., Pearson J.D. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. J Am Med Assoc 1997, 277(18):1456-1460.
24. Kuller L.H., Thomas A., Grandits G., Neaton J.D. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(3):373-377.
25. Vickers A.J., Cronin A.M., Björk T., Manjer J., Nilsson P.M., Dahlin A., et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Br Med J 2010, 341:c4521.
26. Connolly D., Black A., Gavin A., Keane P.F., Murray L.J. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 2008, 17(2):271-278.
27. Schaeffer E.M., Carter H.B., Kettermann A., Loeb S., Ferrucci L., Landis P., et al. Prostate specific antigen testing among the elderly-when to stop?. J Urol 2009, 181(4):1606-1614. [discussion 1613-1614].
28. Tang P., Sun L., Uhlman M.A., Polascik T.J., Freedland S.J., Moul J.W. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer 2010, 116(20):4711-4717.
29. Loeb S., Roehl K.A., Antenor J.A.V., Catalona W.J., Suarez B.K., Nadler R.B. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006, 67(2):316-320.
30. Gulati R., Gore J.L., Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013, 158(3):145-153.